文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET/CT在前列腺癌评估中的观察者间一致性:一项国际多中心前瞻性研究

68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.
PubMed 文献 · J Nucl Med · 2017-04-13

本研究纳入50例前列腺癌患者行68Ga-PSMA-11 PET/CT,由16名观察者按标准化方法判读局部、淋巴结、骨和内脏转移,参考标准为组织病理学、放疗后PSA反应或随访PET/CT。高经验观察者在淋巴结和骨评估中一致性高,低经验者总体一致性和T分期特异性显著较低,作者建议初始培训至少30例患者。

要点

  • 全部观察者间T分期一致性为κ=0.62(95%CI 0.59-0.64),N分期为κ=0.74(95%CI 0.71-0.76)。
  • 骨转移(Mb)分期一致性几乎完美,κ=0.88(95%CI 0.86-0.91),且不受经验水平影响。
  • 低经验者总体一致率中位数54% vs 中等经验66%和高经验76%(P=0.041),T分期特异性73% vs 88%和93%(P=0.032)。

核心结论

  • 高经验观察者对68Ga-PSMA-11 PET/CT前列腺癌分期判读高度一致,尤其在淋巴结和骨评估方面。
  • 作者建议初始培训至少30例患者以确保可接受的判读性能。

研究设计与样本

  • 国际多中心前瞻性研究,50例前列腺癌患者行68Ga-PSMA-11 PET/CT。
  • 适应症包括生化复发(n=25)、原发诊断(n=10)、原发治疗后生化持续(n=5)或已知转移性疾病分期(n=10)。
  • 16名观察者按标准化方法判读局部(T)、淋巴结(N)、骨(Mb)或内脏(Mc)受累。
  • 观察者经验分级:低经验(<30例既往68Ga-PSMA-11 PET/CT,n=5)、中等经验(30-300例,n=5)、高经验(>300例,n=6)。
  • 参考标准为组织病理学(n=25,50%)、外照射放疗后前列腺特异性抗原反应(n=15,30%)或随访PET/CT(n=10,20%)。

主要发现

  • 全部观察者间T分期一致性为κ=0.62(95%CI 0.59-0.64),N分期为κ=0.74(95%CI 0.71-0.76),Mb分期为κ=0.88(95%CI 0.86-0.91)。
  • 经验水平与T分期一致性正相关:高/中/低经验组κ分别为0.73/0.66/0.50。
  • 经验水平与N分期一致性正相关:高/中/低经验组κ分别为0.80/0.76/0.64。
  • 经验水平与Mc分期一致性正相关:高/中/低经验组κ分别为0.61/0.46/0.36。
  • Mb分期一致性几乎完美且不受经验影响:高/中/低经验组κ分别为0.87/0.91/0.88。

关键数值与推荐

  • T分期一致性κ=0.62(95%CI 0.59-0.64),N分期κ=0.74(95%CI 0.71-0.76),Mb分期κ=0.88(95%CI 0.86-0.91)。
  • 高/中/低经验组T分期κ分别为0.73/0.66/0.50,N分期κ分别为0.80/0.76/0.64,Mc分期κ分别为0.61/0.46/0.36。
  • 高/中/低经验组Mb分期κ分别为0.87/0.91/0.88。
  • 低经验组总体一致率中位数54% vs 中等经验组66%和高经验组76%(P=0.041)。
  • 低经验组T分期特异性73% vs 中等经验组88%和高经验组93%(P=0.032)。

临床怎么用

  • 作者建议初始培训至少30例患者以确保可接受的判读性能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The interobserver agreement for 68Ga-PSMA-11 PET/CT study interpretations in patients with prostate cancer is unknown. Methods:68Ga-PSMA-11 PET/CT was performed in 50 patients with prostate cancer for biochemical recurrence (n = 25), primary diagnosis (n = 10), biochemical persistence after primary therapy (n = 5), or staging of known metastatic disease (n = 10). Images were reviewed by 16 observers who used a standardized approach for interpretation of local (T), nodal (N), bone (Mb), or visceral (Mc) involvement. Observers were classified as having a low (<30 prior 68Ga-PSMA-11 PET/CT studies; n = 5), intermediate (30-300 studies; n = 5), or high level of experience (>300 studies; n = 6). Histopathology (n = 25, 50%), post-external-beam radiation therapy prostate-specific antigen response (n = 15, 30%), or follow-up PET/CT (n = 10, 20%) served as a standard of reference. Observer groups were compared by overall agreement (% patients matching the standard of reference) and Fleiss' κ with mean and corresponding 95% confidence interval (CI). Results: Agreement among all observers was substantial for T (κ = 0.62; 95% CI, 0.59-0.64) and N (κ = 0.74; 95% CI, 0.71-0.76) staging and almost perfect for Mb (κ = 0.88; 95% CI, 0.86-0.91) staging. Level of experience positively correlated with agreement for T (κ = 0.73/0.66/0.50 for high/intermediate/low experience, respectively), N (κ = 0.80/0.76/0.64, respectively), and Mc staging (κ = 0.61/0.46/0.36, respectively). Interobserver agreement for Mb was almost perfect irrespective of prior experience (κ = 0.87/0.91/0.88, respectively). Observers with low experience, when compared with intermediate and high experience, demonstrated significantly lower median overall agreement (54% vs. 66% and 76%, P = 0.041) and specificity for T staging (73% vs. 88% and 93%, P = 0.032). Conclusion: The interpretation of 68Ga-PSMA-11 PET/CT for prostate cancer staging is highly consistent among observers with high levels of experience, especially for nodal and bone assessments. Initial training on at least 30 patient cases is recommended to ensure acceptable performance.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fendler WP, Calais J, Allen-Auerbach M, et al. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med. 2017. PMID: 28408531. doi:10.2967/jnumed.117.190827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。